Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. develops clinical-stage drug candidates for neurodegenerative disorders, with news centered on zervimesine (CT1812), an investigational oral small molecule designed to protect neuronal synapses from toxic protein oligomers. Company updates commonly address dementia with Lewy bodies, Alzheimer’s disease, mild cognitive impairment, and geographic atrophy secondary to dry AMD.
Recurring developments include Phase 2 study data from programs such as SHIMMER and START, regulatory interactions with U.S. and European agencies, scientific conference presentations, expanded access activity, and quarterly financial results. News also covers NIH-related grant funding, cash runway commentary, and clinical-development plans tied to zervimesine’s use across central nervous system and retina indications.
Summary not available.
Summary not available.
Summary not available.
Cognition Therapeutics will present in vitro results on the role of sigma-2 receptors and the effect of their drug candidate CT1812 on dry age-related macular degeneration (AMD) at the upcoming ARVO meeting in New Orleans from April 23-27.
CT1812, an orally delivered small molecule, targets sigma-2 receptors and shows potential in modulating biological pathways affected by dry AMD, including immune response and cell survival. The detailed findings will be showcased in poster #C0072 during the conference.
The company is also preparing for a Phase 2 clinical trial of CT1812 for geographic atrophy linked to dry AMD, with clinical site selection currently underway. The drug is under investigation for mild-to-moderate Alzheimer's disease and dementia with Lewy bodies as well.
Cognition Therapeutics announced the publication of a review article in the International Journal of Molecular Sciences discussing the mechanistic rationale for sigma-2 receptor modulation in age-related degenerative diseases including Alzheimer's disease and dementia with Lewy bodies. The article highlights the role of the sigma-2 receptor in neuronal function and its potential as a therapeutic target. Cognition's lead compound, CT1812, aims to advance to Phase 2 clinical trials. The study focuses on restoring synaptic health by targeting cellular processes impaired by neurodegenerative diseases. Cognition’s strategy underscores the unique mechanism of CT1812 in addressing significant unmet medical needs in neurodegeneration.
On March 28, 2023, Cognition Therapeutics (NASDAQ: CGTX) disclosed findings from a meta-analysis involving 24 participants in the Phase 2 SHINE-A study and data from the Phase 1b SPARC study. The results indicate that treatment with CT1812 yields statistically significant effects on key Alzheimer's disease markers, notably improving synapse health and reducing neuroinflammation. Notable changes in cerebrospinal fluid levels of clusterin and prion protein were observed, underscoring CT1812's potential in altering disease processes. These results were presented at the AD/PD™ 2023 conference, enhancing understanding of CT1812's therapeutic effects.
Cognition Therapeutics (Nasdaq: CGTX) has released its fourth video podcast discussing dementia with Lewy bodies (DLB), featuring insights from four neuroscience experts. The podcast highlights the overlap between DLB, Alzheimer’s, and Parkinson’s diseases, including symptoms, clinical features, and the importance of accurate diagnosis. Currently, there are no approved disease-modifying treatments for DLB, which affects about 1.4 million Americans. The company is conducting the Phase 2 SHIMMER study for its lead candidate, CT1812, with a $30M grant from the NIH’s National Institute on Aging to evaluate treatment effects on DLB.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has announced significant progress in its clinical development, including the completion of enrollment in the Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease. The company received FDA clearance for the Phase 2 START study and the IND for a Phase 2 study targeting geographic atrophy due to dry AMD. Financially, the company secured an equity commitment of up to $35 million and raised $6 million through a public offering, with cash reserves expected to fund operations into the second half of 2024. However, Cognition reported a net loss of $21.4 million for 2022, reflecting increased R&D and G&A expenses.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) will present results from a proteomic biomarker meta-analysis of cerebrospinal fluid samples from participants in their Phase 2 SHINE and Phase 1b SPARC studies, focusing on mild-to-moderate Alzheimer's disease. The analysis identified biomarkers of CT1812 activity, which inform the understanding of Alzheimer's progression. A poster presentation is scheduled at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. Additionally, CEO Lisa Ricciardi will participate in a panel on innovative approaches to Alzheimer's research on March 29, emphasizing the importance of rigorous clinical trials.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced a conference call set for March 23, 2023, at 8:00 a.m. ET to review its financial results for the fourth quarter and full year ended December 31, 2022. The results will be released before the market opens on the same day. Participants can access the call via a toll-free dial-in or through a live audio webcast on the company's Investor Relations page. Cognition is focused on developing treatments for neurodegenerative disorders, with its lead candidate CT1812 targeting Alzheimer's and related conditions.